Cytek Biosciences grants legal chief 25,745 stock units

Available on EDGAR 11/12/2026 - 08:43 PM EST Accepted by SEC EDGAR 11/12/2026 - 08:43 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Cytek Biosciences, Inc. Chief Legal Officer and Secretary Ilan Feuchtwang received a direct award of 25,745 restricted stock units on November 9, 2026. Each RSU represents a contingent right to receive one common share. The RSUs vest and settle over four years, beginning November 18, 2027, subject to Ilan Feuchtwang’s Continuous Service.

Insider Trade Summary

Grant/Award: 25,745 shares

Grant/Award 1 txn

Insider Feuchtwang Ilan

Role Chief Legal Officer, Secretary

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units F1, F2	25,745	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 25,745 units (Direct)

Holdings Before and After: Restricted Stock Units, 0 to 25,745 units (Direct)

Footnotes (2)

1. F1. Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock.
2. F2. The RSUs shall vest and settle into common stock over 4 years, with 12/48 of the RSUs vesting on November 18, 2027; 4/48 of the RSUs vesting on March 10, 2028 and each March 10 thereafter; 2/48 of the RSUs vesting on May 18, 2028 and each May 18 thereafter; 3/48 of the RSUs vesting on August 18, 2028 and each August 18 thereafter, and 3/48 of the RSUs vesting on November 18, 2028 and each November 18 thereafter, until fully vested (in each case, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan (the "2021 Plan"))).

Key Figures

RSUs awarded: 25,745 RSUs

1 metrics

RSUs awarded 25,745 RSUs Direct award to Ilan Feuchtwang on November 9, 2026; each RSU represents a contingent right to receive one common share.

Key Terms

restricted stock unit, Continuous Service, 2021 Equity Incentive Plan

3 terms

restricted stock unit financial

"Each restricted stock unit (the “RSU”) represents a contingent right to receive one share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Continuous Service technical

"subject to the Reporting Person’s Continuous Service"

2021 Equity Incentive Plan technical

"as defined in the Issuer’s 2021 Equity Incentive Plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RSUs did CTKB’s chief legal officer receive?

Chief Legal Officer and Secretary Ilan Feuchtwang received 25,745 RSUs on November 9, 2026. Each RSU represents a contingent right to receive one common share.

What is the vesting schedule for Ilan Feuchtwang’s CTKB RSUs?

The RSUs vest and settle over four years, subject to Ilan Feuchtwang’s Continuous Service: 12/48 on November 18, 2027; 4/48 on March 10, 2028 and each March 10 thereafter; 2/48 on May 18, 2028 and each May 18 thereafter; and 3/48 on August 18, 2028 and each August 18 thereafter, plus 3/48 on November 18, 2028 and each November 18 thereafter, until fully vested.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Feuchtwang Ilan

(Last) (First) (Middle)

C/O CYTEK BIOSCIENCES, INC.

47215 LAKEVIEW BOULEVARD

(Street)

FREMONT CALIFORNIA 94538

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cytek Biosciences, Inc. [ CTKB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer, Secretary

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	11/09/2026		A		25,745		(2)	(2)	Common Stock	25,745	$0	25,745	D

Explanation of Responses:

1. Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock.

2. The RSUs shall vest and settle into common stock over 4 years, with 12/48 of the RSUs vesting on November 18, 2027; 4/48 of the RSUs vesting on March 10, 2028 and each March 10 thereafter; 2/48 of the RSUs vesting on May 18, 2028 and each May 18 thereafter; 3/48 of the RSUs vesting on August 18, 2028 and each August 18 thereafter, and 3/48 of the RSUs vesting on November 18, 2028 and each November 18 thereafter, until fully vested (in each case, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan (the "2021 Plan"))).

	/s/ Wenbin Jiang, Attorney-in-Fact	11/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)